+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease



Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease



Arthritis and Rheumatology 69(1): 194-202



To describe systemic autoimmune joint diseases that develop following Lyme disease, and to compare their clinical features with those of Lyme arthritis (LA). We reviewed records of all adult patients referred to our LA clinic over a 13-year period, in whom we had diagnosed a systemic autoimmune joint disease following Lyme disease. For comparison, records of patients enrolled in our LA cohort over the most recent 2-year period were analyzed. Levels of IgG antibodies to Borrelia burgdorferi and to 3 Lyme disease-associated autoantigens were measured. We identified 30 patients who had developed a new-onset systemic autoimmune joint disorder a median of 4 months after Lyme disease (usually manifested by erythema migrans [EM]). Fifteen had rheumatoid arthritis (RA), 13 had psoriatic arthritis (PsA), and 2 had peripheral spondyloarthritis (SpA). The 30 patients typically had polyarthritis, and those with PsA or SpA often had previous psoriasis, axial involvement, or enthesitis. In the comparison group of 43 patients with LA, the usual clinical picture was monoarticular knee arthritis, without prior EM. Most of the patients with systemic autoimmune joint disorders were positive for B burgdorferi IgG antibodies, as detected by enzyme-linked immunosorbent assay, but had significantly lower titers and lower frequencies of Lyme disease-associated autoantibodies than patients with LA. Prior to our evaluation, these patients had often received additional antibiotics for presumed LA, without benefit. We prescribed antiinflammatory agents, most commonly disease-modifying antirheumatic drugs, resulting in improvement. Systemic autoimmune joint diseases (i.e., RA, PsA, SpA) may follow Lyme disease. Development of polyarthritis after antibiotic-treated EM, previous psoriasis, or low-titer B burgdorferi antibodies may provide insight into the correct diagnosis.

(PDF emailed within 0-6 h: $19.90)

Accession: 057271001

Download citation: RISBibTeXText

PMID: 27636905

DOI: 10.1002/art.39866


Related references

A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Plos One 10(4): E0123582, 2016

Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database of Systematic Reviews 2011(10): Cd008886, 2011

First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. Annals of the Rheumatic Diseases 73(10): 1905-1906, 2015

Rheumatology (rheumatoid arthritis, psoriatic arthritis, Spondyloarthritis): What are the most important innovations in the last 10 years?. Mmw Fortschritte der Medizin 160(Suppl 3): 50-54, 2018

Interleukin-2 is found in the synovium of psoriatic arthritis and spondyloarthritis, not in rheumatoid arthritis. Scandinavian Journal of Rheumatology 25(4): 239-245, 1996

Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45(5): 519-532, 2016

Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. European Journal of Clinical Investigation 48(11): E13013, 2018

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care and Research 69(11): 1692-1699, 2017

Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database of Systematic Reviews 2012(11): Cd008872, 2012

Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis. Arthritis Care and Research 70(12): 1756-1763, 2018

Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clinical and Experimental Rheumatology 33(4): 559-569, 2015

THU0327Psychometric Properties of Paindetect in Rheumatoid Arthritis, Psoriatic Arthritis and Other Spondyloarthritis: Rasch Analysis and Test-Retest Reliability. Annals of the Rheumatic Diseases 74(Suppl 2): 314.1-314, 2015

AB0068Distribution of blood dendritic cell subsets in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis treated with etanercept. Annals of the Rheumatic Diseases 71(Suppl 3): 641.11-641, 2013

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference and Adherence 11: 519-530, 2017

SAT0578Patients with Rheumatoid Arthritis, Spondyloarthritis and Psoriatic Arthritis Treated with BIOLOGICS Use Similar Coping Strategies: A Study of 671 Patients:. Annals of the Rheumatic Diseases 73(Suppl 2): 799.2-799, 2014